Published in Brain on November 16, 2009
Inflammation in neurodegenerative diseases. Immunology (2010) 3.22
Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings. Mult Scler (2013) 1.45
Inflammation in neurodegenerative diseases--an update. Immunology (2014) 1.30
The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist (2010) 1.28
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler (2011) 1.24
Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci (2012) 1.04
Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. Biochim Biophys Acta (2010) 1.00
Virus infection, antiviral immunity, and autoimmunity. Immunol Rev (2013) 1.00
Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to Epstein-Barr virus and multiple sclerosis. PLoS Pathog (2012) 0.96
Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis. Mult Scler (2012) 0.94
Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation. Viruses (2012) 0.93
Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog (2013) 0.92
Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Transl Immunology (2014) 0.92
Viruses and multiple sclerosis. Neuroscientist (2011) 0.90
Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Ther Adv Neurol Disord (2013) 0.89
Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurol Neuroimmunol Neuroinflamm (2016) 0.85
Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis ? Acta Neuropathol Commun (2015) 0.84
Cortical injury in multiple sclerosis; the role of the immune system. BMC Neurol (2011) 0.83
A complex role of herpes viruses in the disease process of multiple sclerosis. PLoS One (2014) 0.82
Multiple sclerosis: are protective immune mechanisms compromised by a complex infectious background? Autoimmune Dis (2010) 0.81
Epstein-Barr virus stimulates torque teno virus replication: a possible relationship to multiple sclerosis. PLoS One (2012) 0.80
The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Prog Neurobiol (2015) 0.79
Quantitative detection of epstein-barr virus DNA in cerebrospinal fluid and blood samples of patients with relapsing-remitting multiple sclerosis. PLoS One (2014) 0.79
Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system? Clin Exp Immunol (2012) 0.78
The role of the Epstein-Barr virus in the pathogenesis of some autoimmune disorders - Similarities and differences. Eur J Microbiol Immunol (Bp) (2011) 0.77
The Role of Latently Infected B Cells in CNS Autoimmunity. Front Immunol (2015) 0.75
Programmed death 1 is highly expressed on CD8+CD57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to EBV. Immunology (2017) 0.75
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A (2010) 6.72
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res (2010) 4.77
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Inflammation in neurodegenerative diseases. Immunology (2010) 3.22
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet (2013) 2.89
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol (2009) 2.82
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain (2003) 2.63
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 2.55
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet (2008) 2.45
The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. Neurology (2003) 2.35
Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A (2003) 2.31
Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol (2008) 2.29
Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis. J Infect Dis (2013) 2.19
A randomised cross-over trial investigating the ease of use and preference of two dry powder inhalers in patients with asthma or chronic obstructive pulmonary disease. Expert Opin Drug Deliv (2013) 2.13
Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A (2007) 2.13
Testicular hypofunction and multiple sclerosis risk: a record-linkage study. Ann Neurol (2014) 2.09
Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol (2010) 2.08
Exosomes: Fit to deliver small RNA. Commun Integr Biol (2010) 1.93
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation (2009) 1.77
The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol (2005) 1.76
C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc Natl Acad Sci U S A (2012) 1.73
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler (2012) 1.71
Cytomegalovirus (CMV) inactivation in breast milk: reassessment of pasteurization and freeze-thawing. Pediatr Res (2004) 1.71
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69
EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol (2004) 1.68
Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol (2010) 1.64
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum (2006) 1.62
Critical appraisal of animal models of multiple sclerosis. Mult Scler (2011) 1.61
Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol (2012) 1.61
Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation (2013) 1.59
Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J Clin Invest (2003) 1.59
Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol (2003) 1.55
Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet (2013) 1.55
Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol (2002) 1.54
Identification of a microglia phenotype supportive of remyelination. Glia (2011) 1.51
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain (2005) 1.51
The therapeutic potential of cannabis. Lancet Neurol (2003) 1.49
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46
Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans. Genome Res (2012) 1.45
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology (2014) 1.45
Month of birth, vitamin D and risk of immune-mediated disease: a case control study. BMC Med (2012) 1.44
Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology (2013) 1.44
Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology (2012) 1.41
Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer (2006) 1.41
Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol (2007) 1.40
Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog (2009) 1.39
HERVs: have we been here before? Mult Scler (2012) 1.39
Obsessive-compulsive disorder and catatonia can be caused by antibasal ganglia antibodies. Cogn Behav Neurol (2007) 1.39
Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis (2004) 1.38
Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer (2012) 1.38
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry (2011) 1.37
Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study. J Neuropathol Exp Neurol (2010) 1.36
An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One (2010) 1.36
Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteomics (2010) 1.36
Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol (2007) 1.36
Stiff person syndrome. Pract Neurol (2011) 1.36
Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol (2009) 1.36
Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. J Infect Dis (2012) 1.35
The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry (2012) 1.34
LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-κB activation. EMBO J (2011) 1.34
Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion (2010) 1.34
Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One (2013) 1.32
Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol (2007) 1.32
Inflammation in neurodegenerative diseases--an update. Immunology (2014) 1.30
The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. J Virol (2007) 1.29
Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol (2009) 1.29
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther (2006) 1.28
Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. Arch Neurol (2009) 1.26
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J Infect Dis (2009) 1.25
Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma (2002) 1.25
Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis (2008) 1.24
Prevalence and clinical consequences of herpes simplex virus type 1 DNA in human cornea tissues. J Infect Dis (2009) 1.23
Longterm quiescent cells in the aged human subventricular neurogenic system specifically express GFAP-delta. Aging Cell (2010) 1.22
Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem (2010) 1.22
Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis (2009) 1.22
The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol (2007) 1.20
In vitro and in vivo models of multiple sclerosis. CNS Neurol Disord Drug Targets (2012) 1.20
IL-17 expression in human herpetic stromal keratitis: modulatory effects on chemokine production by corneal fibroblasts. J Immunol (2002) 1.19
Comparison of quantitative competitive PCR with LightCycler-based PCR for measuring Epstein-Barr virus DNA load in clinical specimens. J Clin Microbiol (2002) 1.19
Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry (2013) 1.19